Estados Unidos · Plataformas y datos · MarketBeat

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

Publicado por MarketBeat · Estados Unidos hace 1 h

Prelude Therapeutics (NASDAQ:PRLD) outlined progress across three priority programs at a Chardan Capital investor session, emphasizing its recently initiated JAK2 program, an…

Leer el artículo completo en MarketBeat Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.marketbeat.com)

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

También te puede interesar

Deckers projects FY2027 revenue $5.7B-$5.725B and EPS $7.80-$7.95 amid higher U.S. promotions

I've Covered Tesla for Over a Decade. Here's Whether It's a Stock to Buy More Than 21% Below Its Record.

+34%, +25%, +21%: 3 stocks the smart money quietly bought in October

My partner of 17 years left me his $1 million home. His children are crying foul. Am I obliged to split it with them?

Nasdaq Futures Rise After Chip Selloff While S&P 500, Dow Track Mixed Open: SLV, GLD, SOXL, BE In Focus

Han's Laser Receives the "Shenzhen Green Factory" Designation

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

Compartir

También te puede interesar

Deckers projects FY2027 revenue $5.7B-$5.725B and EPS $7.80-$7.95 amid higher U.S. promotions

I've Covered Tesla for Over a Decade. Here's Whether It's a Stock to Buy More Than 21% Below Its Record.

+34%, +25%, +21%: 3 stocks the smart money quietly bought in October

My partner of 17 years left me his $1 million home. His children are crying foul. Am I obliged to split it with them?

Nasdaq Futures Rise After Chip Selloff While S&P 500, Dow Track Mixed Open: SLV, GLD, SOXL, BE In Focus

Han's Laser Receives the "Shenzhen Green Factory" Designation